Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inducing synthetic lethality for selective targeting of acute myeloid leukemia cells harboring STAG2 mutations.

Haematologica - 1 Sept 2022

Subramaniam Agatheeswaran, Sandén Carl, Moura-Castro Larissa, Žemaitis Kristijonas, Schmiderer Ludwig, Baudet Aurelie, Bäckström Alexandra, Arvidsson Elin, Hultmark Simon, Miharada Natsumi, Magnusson Mattias, Paulsson Kajsa, Fioretos Thoas, Larsson Jonas

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle Proteins
Share to Leukemia, Myeloid, Acute
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Synthetic Lethal Mutations

Source

Open in PubMed Open full text

Identifiers

PMID: 35638550
DOI: 10.3324/haematol.2021.280303
PMCID: PMC9425301

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inducing synthetic lethality for selective targeting of acute myeloid leukemia cells harboring STAG2 mutations.PMID 35638550Read ↗

Inducing synthetic lethality for selective targeting of acute myeloid leukemia cells harboring <i>STAG2</i> mutationsSemantic proximity Read ↗

Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy.Semantic proximity Read ↗

Synthesis and Evaluation of a Class of Compounds Inhibiting the Growth of Stromal Antigen 2 (STAG2)-Mutant Ewing Sarcoma Cells.Semantic proximity Read ↗

Applying synthetic lethality for the selective targeting of cancer.Semantic proximity Read ↗

Cutting down the time to identify challenging tumor therapeutic targets and drug combinations using synthetic lethal approachesSemantic proximity Read ↗

Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation.Semantic proximity Read ↗

Reduced BAP1 activity prevents ASXL1 truncation-driven myeloid malignancy in vivo.Semantic proximity Read ↗

A lethal combination for cancer cells: synthetic lethality screenings for drug discovery.Semantic proximity Read ↗

The power and the promise of synthetic lethality for clinical application in cancer treatmentSemantic proximity Read ↗

Development of small-molecule probes that selectively kill cells induced to express mutant RAS.Semantic proximity Read ↗

Targeted therapy-induced differentiation of acute myeloid leukemia blasts.Semantic proximity Read ↗

Development of synthetic lethality in cancer: molecular and cellular classification.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.